Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
NK cell therapy is gaining momentum as a promising solution to unmet medical needs in cancer treatment, offering safer, tar ...
Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...
Medpage Today on MSN3d
Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid TumorsAn obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...
Dr. Reddy's Laboratories Limited ( NYSE: RDY) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financial Officer Erez ...
Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 ...
Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...
BIRMINGHAM, Ala. (WIAT) — The Jefferson County Senior Services Division is hosting The MMRF Multiple Myeloma Community Connect event on Thursday, Nov. 14. Odessa Woolfolk honored with human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback